Nasdaq

SAB BIO Secures $175 Million in Private Placement Financing to Advance Phase 2b SAFEGUARD Study for Autoimmune T1D Treatment

SAB BIO has announced a $175 million private placement financing to fund its pivotal Phase 2b SAFEGUARD study of SAB-142, aimed at delaying the progression of autoimmune type 1 diabetes (T1D) in newly ...
Yahoo Finance

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting

MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human ...
The Financial Express

SAB Industries Share Price

Click to deselect and select. Feb 13, 2026, 10:52 PM IST IST SAB Industries - Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2025 Feb 13, 2026, 10:43 PM IST IST SAB Industries ...
Yahoo Finance

SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza

SIOUX FALLS, S.D., April 13, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...
Seeking Alpha

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

The ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading ...
News24

SAB gets new logo – which represents SA future with 'more cheers'

SAB has launched a new, more modern logo. Its CEO believes better times lie ahead for South Africa thanks to a growing youthful population. A merged Heineken and Distell group could bring more ...